January 11, 2023
Padagis today announced the FDA approval and launch of an AB-rated generic version of MIRVASO® (brimonidine) topical gel, 0.33%.
Brimonidine Topical Gel, 0.33%* is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Padagis President and CEO, Sharon Kochan, stated “This FDA approval and launch demonstrates our commitment to bringing complex, specialized products to patients and customers nationwide who are in search of high quality, affordable specialized healthcare products.”
Padagis is a leading provider of extended topical and other specialty pharmaceuticals to its primary markets of the United States and Israel. Padagis employs over 1,300 people worldwide.